DRG International, Inc.  

Springfield,  NJ 
United States
http://www.drg-international.com
  • Booth: 3438

Booth Profile

DRG International, Inc., founded in 1970 in the USA, is a global innovator of high-quality medical diagnostics and equipment, providing the medical and research community with cutting edge, effective tools to build a healthier future. NEW ELISAS: >Salivary Hormone (Optimized) ELISAS >Salivary Hepcidin ELISA (SLV6082) >Hepcidin 25 (bioactive) HS (serum/plasma) ELISA (EIA5782) >Aldosterone (EIA5298) >Active Renin (EIA5125) >25-OH Vitamin D (EIA5396) > NEW DRG:Hybrid•XL ASSAYS! >NEW DRG:Hybrid•XL FULLY AUTOMATED IMMUNOASSAY & CLINICAL CHEMISTRY ANALYZER Please visit www.drg-international.com for details!


 Press Releases

  • FOR IMMEDIATE RELEASE

    Contact:                 Gregory Guest

                                    (973) 564-7555

                                    marketing@drg-international.com

    DRG® Aldosterone ELISA Kit at the 2018 AACC (Booth# 3438)

    - Diagnostic and Research product manufacturer to showcase ELISA kit which differentiates between primary and secondary Aldosteronism -

    Springfield, New Jersey, USA (July 2018)— DRG International, a leading international medical diagnostic company, will showcase its DRG® Aldosterone ELISA Kit at the 2018 AACC Conference in Chicago, Illinois from July 29 – August 2.  The DRG International Aldosterone ELISA is for measurement of Aldosterone in serum, plasma, and urine.

    Aldosterone regulates levels of sodium and potassium in the body and also controls blood pressure as well as fluids and electrolytes in the blood.  Measurement of aldosterone levels in serum in conjunction with plasma renin levels (aldosterone/renin-ratio; ARR) can be used to differentiate between primary and secondary aldosteronism. The differentiation is vital in the treatment and management of the disease.

    “The importance of testing Aldosterone is growing in the research and clinical communities,” said Dr. Matthias Herkert, Senior Scientist of DRG Instruments Gmbh.  “The accuracy and ease of use of this kit make it a top choice of researchers world-wide.”

    The DRG® Aldosterone ELISA Kit (EIA-5298R) is an exciting addition to the laboratory field. It is a solid phase enzyme-linked immunosorbent assay (ELISA) based on the competitive principle. The Aldosterone ELISA Kit is available globally, and for research use only in the United States.


    DRG International will be showcasing at the AACC in Booth-3438.  Press inquiries are welcome. For more information, please contact Gregory Guest (Marketing Manager for DRG International) at (973) 564-7555.


    ~*~

     

    DRG International, Inc. founded in 1970, is a multinational specialty medical equipment and diagnostics manufacturer and distributor with successful operations in over 110 countries.

    DRG supplies an extensive line of immunodiagnostic products including fertility and pregnancy tests, endocrinology/diabetes, saliva hormone diagnostics, tumor markers, infectious diseases, immunology/hematology, thyroid function panels, cardiovascular assays as well as therapeutic and toxicology screening products. To obtain more information about the DRG group of companies and complete product line, please visit our New website at:  www.drg-international.com

  • FOR IMMEDIATE RELEASE

    Contact:               Gregory Guest

                                    (973) 564-7555

                                    marketing@drg-international.com

    DRG® Hepcidin Salivary Elisa to Showcase at 2018 AACC (Booth# 3438)

    -This revolutionary testing kit will be on display, with DRG scientific team on hand for in-depth discussion-

    Springfield, New Jersey, USA (July 2018)- DRG International, a leading international medical diagnostic company, will showcase the NEW DRG® Hepcidin Salivary ELISA Kit (SLV-6082) at the 2018 AACC Conference in Chicago, Illinois from July 29 – August 2.  As the first of its kind to market, this kit accurately detects bioactive Hepcidin levels in saliva samples as an additional marker to aid in identifying a variety of disorders.  In recent years, a large number of publications identify Hepcidin as a factor in regulating the amount of iron in humans.  Unbalanced iron level can lead to many common medical conditions including anemia and iron overload disease, and can occur in chronic kidney disease, inflammation, or diabetes mellitus.

    The DRG® Hepcidin Salivary ELISA Kit (SLV-6082) is available worldwide, providing a simple, fast and accurate method to test Hepcidin levels. Some of the kit features include:

    • Range: 125 – 8,000 pg/ml
    • Incubation: 60/30 min
    • Sample Volume: 100 µLSaliva

    DRG currently holds 17 US and International active patents on this product. The measurement results of this kit offer more information to help treat medical issues including iron deficiency diseases, which are some of the most common diseases worldwide. The kit is for Research Use Only (RUO) in the United States and is also CE marked.

    DRG International will be showcasing at the AACC in Booth-3438.  Press inquiries are welcome. For more information, please contact Gregory Guest (Marketing Manager for DRG International) at (973) 564-7555.

    ~*~

    DRG International, Inc. founded in 1970, is a multinational specialty medical equipment and diagnostics manufacturer and distributor with successful operations in over 110 countries.

    DRG supplies an extensive line of immunodiagnostic products including fertility and pregnancy tests, endocrinology/diabetes, saliva hormone diagnostics, tumor markers, infectious diseases, immunology/hematology, thyroid function panels, cardiovascular assays as well as therapeutic and toxicology screening products. To obtain more information about the DRG group of companies and complete product line, please visit our New website at:  www.drg-international.com

  • FOR IMMEDIATE RELEASE

    Contact:                 Gregory Guest

                                    (973) 564-7555

                                    marketing@drg-international.com

    DRG® Renin (active) ELISA to be showcased at 2018 AACC (Booth# 3438)

    - This industry-leading ELISA testing kit for hypertension detection to be presented by DRG team -

    Springfield, New Jersey, USA (July 2018)- DRG International’s Renin (Active) ELISA for testing of active Renin in human EDTA plasma will be on display at the AACC’s 2018 show in Chicago, Illinois from July 29 – August 2. The DRG® Renin active ELISA test is accurate in testing for certain types of hypertension and has been utilized by labs world-wide.

    By measuring the active renin levels in a sample, the DRG® Renin (Active) ELISA (EIA-5125R) can also effectively detect hypertension in a pregnancy. This early discovery opens up a much more effective array of treatment methods for the patient.

    “The DRG Renin (Active) ELISA Kit allows research laboratories to quickly and easily measure for Renin,” said Dr. Matthias Herkert, Senior Scientist of DRG Instruments GmbH. “The accuracy of our test has made it the top choice of researchers in the field and its applications continue to grow.”

    The DRG Renin (Active) ELISA is a solid phase enzyme-linked immunosorbent assay based on the sandwich principle.

    DRG® International, Inc. is committed to providing the medical and research community with cutting edge, easy-to-use and effective diagnostic equipment. DRG® International is constantly looking towards the future in order to continue to produce and distribute the highest-quality products.


    DRG International will be showcasing at the AACC in Booth-3438.  Press inquiries are welcome. For more information, please contact Gregory Guest (Marketing Manager for DRG International) at (973) 564-7555.


    ~*~

     

    DRG International, Inc. founded in 1970, is a multinational specialty medical equipment and diagnostics manufacturer and distributor with successful operations in over 110 countries.

    DRG supplies an extensive line of immunodiagnostic products including fertility and pregnancy tests, endocrinology/diabetes, saliva hormone diagnostics, tumor markers, infectious diseases, immunology/hematology, thyroid function panels, cardiovascular assays as well as therapeutic and toxicology screening products. To obtain more information about the DRG group of companies and complete product line, please visit our New website at:  www.drg-international.com

  • FOR IMMEDIATE RELEASE

    Contact:               Gregory Guest

                                    (973) 564-7555

                                    marketing@drg-international.com

    DRG® Hepcidin 25 (bioactive) HS Elisa to Showcase at 2018 AACC (Booth# 3438)

    -This revolutionary testing kit will be on display, with DRG scientific team on hand for in-depth discussion-

    Springfield, New Jersey, USA (July 2018)- DRG International, a leading international medical diagnostic company, will showcase the NEW DRG® Hepcidin 25 (bioactive) HS (High Sensitive) ELISA Kit (EIA-5782R) at the 2018 AACC Conference in Chicago, Illinois from July 29 – August 2.  As the first of its kind to market, this kit accurately detects bioactive Hepcidin levels as an additional marker to aid in identifying a variety of disorders.  In recent years, a large number of publications identify Hepcidin as a factor in regulating the amount of iron in humans.  Unbalanced iron level can lead to many common medical conditions including anemia and iron overload disease, and can occur in chronic kidney disease, inflammation, or diabetes mellitus.

    “We at DRG International saw the need for an accurate and easy to use Hepcidin testing kit and are encouraged by the great success that our research customers have seen using the product,” stated Dr. Cyril E. Geacintov, the late founder, President and CEO of DRG International. “This kit is an important step to meet the rapidly growing worldwide interest in Hepcidin testing and the applications of that testing in the health and wellness community.”

    The DRG® Hepcidin 25 (bioactive) HS ELISA Kit is available worldwide, providing a simple, fast and accurate method to test Hepcidin levels. DRG currently holds 17 US and International active patents on this product. The measurement results of this kit offer more information to help treat medical issues including iron deficiency diseases, which are some of the most common diseases worldwide. The kit is for Research Use Only (RUO) in the United States and is also CE marked.

    DRG International will be showcasing at the AACC in Booth-3438.  Press inquiries are welcome. For more information, please contact Gregory Guest (Marketing Manager for DRG International) at (973) 564-7555.

    ~*~

    DRG International, Inc. founded in 1970, is a multinational specialty medical equipment and diagnostics manufacturer and distributor with successful operations in over 110 countries.

    DRG supplies an extensive line of immunodiagnostic products including fertility and pregnancy tests, endocrinology/diabetes, saliva hormone diagnostics, tumor markers, infectious diseases, immunology/hematology, thyroid function panels, cardiovascular assays as well as therapeutic and toxicology screening products. To obtain more information about the DRG group of companies and complete product line, please visit our New website at:  www.drg-international.com

  • FOR IMMEDIATE RELEASE

    Contact:               Gregory Guest

                                    (973) 564-7555

                                    marketing@drg-international.com

    DRG® International, Inc. to Showcase at 2018 AACC (Booth 3438)

    DRG Hepcidin Salivary ELISA Kit (SLV-6082)

    AND

    Newly Optimized Saliva ELISA Assays

    Springfield, NJ, USA (July 2018)- DRG International, a leading international medical diagnostic company, will showcase the Newly Optimized DRG® Saliva ELISA Assays at the 2018 AACC in Chicago, IL from July 31 – August 2. DRG is also introducing for the first time the NEW Hepcidin Salivary ELISA Kit (SLV-6082). DRG® Optimized Saliva ELISA Assays are easy-to-use, non-invasive sampling test kits designed for the measurement of the free (unbound) fraction of steroids. These tests allow for simple, patient-friendly measurement of hormone profiles. They are also a reliable measurement of steroids in veterinary saliva samples without further pre-treatment.

    DRG® Optimized Saliva ELISAS include:

    • DHEA
    • Cortisol
    • Estradiol
    • Testosterone
    • Progesterone
    • Estrone (NEWLY OPTIMIZED!!)

    Clear Advantages:

    • FDA CLEARED  TESTS
    • Increased stability and linearity
    • Ready to use reagents and user friendly assays
    • Non-invasive, easy sampling particularly for babies and children
    • Higher diagnostic relevance with reproducible and reliable results compared to serum analytics
    • EXCELLENT CORRELATION TO MASS SPECTROMETRY

    DRG International will be showcasing at the AACC in Booth 3438.  Press inquiries are welcome. For more information, please contact Gregory Guest (Marketing Manager for DRG International) at (973) 564-7555.

    ~*~

    DRG International, Inc. founded in 1970, is a multinational specialty medical equipment and diagnostics manufacturer and distributor with successful operations in over 110 countries.

    DRG supplies an extensive line of immunodiagnostic products including fertility and pregnancy tests, endocrinology/diabetes, saliva hormone diagnostics, tumor markers, infectious diseases, immunology/hematology, thyroid function panels, cardiovascular assays as well as therapeutic and toxicology screening products. To obtain more information about the DRG group of companies and complete product line, please visit our new website at:  www.drg-international.com


 Additional Info

Included in the Export Interest Directory?
Yes
Business Needs:
Direct Sales, Distributor/Agent/Representative, Investor
Products to be exported:
MEDICAL DIAGNOSTICS And RESEARCH PRODUCTS/Instruments
Countries of Interest:
Afghanistan, Albania, Algeria, American Samoa, Angola, Antarctica, Antigua and Barbuda, Argentina, Armenia, Aruba, Australia, Austria, Azerbaijan, Bahamas, Bahrain, Bangladesh, Barbados, Belarus, Belgium, Belize, Bermuda, Bhutan, Bolivia, Bosnia and Herzegovina, Botswana, Brazil, British Indian Ocean Territory, Brunei Darussalam, Bulgaria, Cambodia, Cameroon, Canada, Cape Verde, Cayman Islands, Central African Republic, Chile, China, Colombia, Croatia (Hrvatska), Cuba, Cyprus, Czech Republic, Denmark, Dominica, Dominican Republic, Ecuador, Egypt, El Salvador, Estonia, Ethiopia, Finland, France, France, Metropolitan, French Guiana, French Southern Territories, Georgia, Germany, Greece, Greenland, Grenada, Honduras, Hong Kong, Hungary, Iceland, India, Indonesia, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kazakhstan, Kenya, Korea (South), Kosovo, Kuwait, Kyrgyzstan, Laos, Latvia, Lebanon, Liberia, Libya, Liechtenstein, Lithuania, Luxembourg, Macau, Macedonia, Madagascar, Malaysia, Maldives, Mali, Malta, Mauritania, Mauritius, Moldova, Monaco, Mongolia, Montenegro, Morocco, Mozambique, Nepal, Netherlands, Netherlands Antilles, Norway, Oman, Pakistan, Panama, Paraguay, Peru, Poland, Portugal, Puerto Rico, Qatar, Romania, Russian Federation, Saudi Arabia, Serbia, Singapore, Slovak Republic, Slovenia, South Africa, Spain, Sri Lanka, Sweden, Switzerland, Taiwan, Tanzania, Thailand, Trinidad and Tobago, Tunisia, Turkey, Turkmenistan, Ukraine, United Arab Emirates, United Kingdom, United States, Uruguay, US Minor Outlying Islands, Uzbekistan, Vatican City State, Venezuela, Vietnam, Virgin Islands (British), Virgin Islands (US), Yemen, Yugoslavia, Zambia, Zimbabwe